Table 3: Study participant comorbidities.
Comorbidities |
Control |
PTSD |
p value |
Acid Reflux |
0/39 (0.0%) |
1/39 (2.6%) |
0.314 |
Arthritis |
1/39 (2.6%) |
8/39 (20.5%) |
0.013 |
Asthma |
0/39 (0.0%) |
4/39 (10.3%) |
0.040 |
Diabetes |
0/39 (0.0%) |
4/39 (10.3%) |
0.040 |
Heart Attack/Angina |
0/39 (0.0%) |
1/39 (2.6%) |
0.314 |
Hypercholesterolemia |
2/39 (5.1%) |
2/39 (5.1%) |
1.000 |
Hypertension |
5/39 (12.8%) |
8/39 (20.5%) |
0.362 |
Irritable Bowel Syndrome |
0/39 (0.0%) |
1/39 (2.6%) |
0.314 |
Lupus |
0/39 (0.0%) |
1/39 (2.6%) |
0.314 |
Medullary Sponge Kidney |
1/39 (2.6%) |
0/39 (0.0%) |
0.314 |
Migraine |
0/39 (0.0%) |
4/39 (10.3%) |
0.040 |
Multiple Sclerosis |
0/39 (0.0%) |
1/39 (2.6%) |
0.314 |
Musculoskeletal Injuries |
2/39 (5.1%) |
6/39 (15.4%) |
0.135 |
Nerve Pain |
0/39 (0.0%) |
3/39 (7.7%) |
0.077 |
Oedema |
0/39 (0.0%) |
2/39 (5.1%) |
0.152 |
Skin Disorders |
0/39 (0.0%) |
1/39 (2.6%) |
0.314 |
Sleep Apnoea |
0/39 (0.0%) |
2/39 (5.1%) |
0.152 |
Stroke |
0/39 (0.0%) |
1/39 (2.6%) |
0.314 |
Thyroid Disease |
1/39 (2.6%) |
1/39 (2.6%) |
1.000 |
Ulcers |
0/39 (0.0%) |
1/39 (2.6%) |
0.314 |
A chi square (χ2) test was used for categorical variables and a p < 0.05 was considered significant.